Provided by Tiger Fintech (Singapore) Pte. Ltd.

WUXI BIO

31.460
-0.400-1.26%
Volume:19.34M
Turnover:610.31M
Market Cap:128.01B
PE:35.06
High:32.040
Open:31.860
Low:31.200
Close:31.860
Loading ...

Wuxi Biologics (Cayman) Stock Rallies 2.0% in Hong Kong

Dow Jones
·
Yesterday

WuXi Biologics (Cayman) Inc.'s (HKG:2269) 26% Jump Shows Its Popularity With Investors

Simply Wall St.
·
01 Aug

WuXi Biologics Expands Global Network with New Modular Facility in Singapore to Boost Biologics Manufacturing Capacity

Reuters
·
29 Jul

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 31% Undervalued

Simply Wall St.
·
29 Jul

Wuxi Biologics (Cayman) Stock Advances 1.6% in Hong Kong

Dow Jones
·
28 Jul

HK Movers | WuXi Biologics Jumps 8% as It Expects First-Half Net Profit to Increase By Over 56% YoY

Tiger Newspress
·
25 Jul

HK Movers | Pharma Outsourcing Stocks Rise on Sector Optimism

Tiger Newspress
·
25 Jul

BUZZ-WuXi Biologics touches 1-1/2-year high on robust earnings forecast

Reuters
·
24 Jul

BRIEF-Wuxi Biologics (Cayman) Says Revenue Expected To Increase 16%, Profit Up 54% For HY

Reuters
·
24 Jul

WuXi Biologics Announces Positive Profit Forecast for First Half of 2025

Reuters
·
24 Jul

WuXi Biologics (Cayman) Inc - Increase Due to Strategies and Technology Platforms in Hy

THOMSON REUTERS
·
24 Jul

Wuxi Biologics (Cayman) Stock Rises 2.7% in Hong Kong

Dow Jones
·
23 Jul

BUZZ-China's WuXi XDC jumps to 20-month high on robust earnings forecast

Reuters
·
23 Jul

HK Movers | Biotech Stocks Surge as WuXi AppTec Unit Issues Positive Earnings Alert

Tiger Newspress
·
23 Jul

WuXi XDC Cayman Inc. Announces Positive Profit Outlook with Over 60% Revenue Increase Expected

Reuters
·
23 Jul

BRIEF-Wuxi Biologics Secures FDA Pli Approval For Five Facilities, First For Commercial Pfs Line

Reuters
·
22 Jul

Wuxi Biologics (Cayman) Stock Sheds 1.9% in Hong Kong

Dow Jones
·
21 Jul

WuXi Biologics Secures FDA Approval for Five Facilities, Including First Commercial Pre-Filled Syringe Line

Reuters
·
21 Jul

Wuxi Biologics (Cayman) Stock Climbs 4.0% in Hong Kong

Dow Jones
·
17 Jul

WuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics

Reuters
·
16 Jul